4BIO CAPITAL is a trade name of 4BIO Ventures Management Ltd, which is authorised and regulated by the Financial Conduct Authority, register number 775193
© 2015-2019 by 4BIO Ventures Management Ltd

4BIO Capital participates in $110M Series B Financing to Advance Transformative Gene Therapy Pipeline of Orchard Therapeutics

December 20, 2017

Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced the completion of an oversubscribed $110 million (£85 million) Series B financing, with participation from 4BIO Capital. Read more at Orchard Therapeutics website.

Please reload

ARCHIVE
Please reload

SEARCH BY TAGS
Please reload

FOLLOW US